Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has been granted an antiviral Patent Family 3 titled “Anti-Virus Agent and Method for Treatment of Viral Infection” by the Hong Kong special administrative region, furthering marketing, and manufacturing monopolies for its RECCE® suite of anti-infectives until February 2037.
The company’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as intravenous and topical therapy, RECCE® 435 as an orally administered therapy for bacterial infections, and RECCE® 529 for viral infections
The intellectual property department of Hong Kong has granted claims relating to RECCE® 327 (R327) and anti-viral formulation RECCE® 529 (R529), most notably:
- Composition/method of manufacture of RECCE® anti-infectives
- Use of R327 or R529 for the treatment of viruses having a lipid envelope or coat, examples being SARS-CoV-2 and Coronaviruses, Influenza viruses, HIV, Hepatitis, Ross River and Herpesviruses
- Administration of R327 or R529 by oral, injection, inhalation, and transdermal dose applications.
Promisingly, the patent will help Recce gain a foothold in the pharmaceutical market of Hong Kong which is valued at US$2.3 billion, with a rising demand for chronic disease treatment.
“Highlighting potential”
Recce CEO James Graham said: “We continue to build our patent portfolio in key geographies and major medical markets.
“This newly granted patent by the Hong Kong Special Administrative Region of the People's Republic of China is another endorsement for our commercial and clinical development strategy highlighting the potential of our Australian anti-infective technology.”
About Recce
Recce Pharmaceuticals is developing a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.
Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.
Consequently, Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.